Sanofi to acquire UK vaccine developer Vicebio for up to $1.6 billion

Published 22/07/2025, 09:40
© Reuters.

Investing.com -- French pharmaceutical company Sanofi (NASDAQ:SNY) has agreed to purchase UK-based vaccine developer Vicebio in a deal worth up to $1.6 billion, adding new respiratory vaccine candidates to its pipeline.

The acquisition, announced Tuesday, includes an upfront payment of $1.15 billion with potential additional payments of up to $450 million tied to achieving specific development and regulatory milestones.

Through this purchase, Sanofi aims to strengthen its respiratory vaccines portfolio by acquiring two early-stage vaccine candidates targeting respiratory syncytial virus and human metapneumovirus. The deal also gives Sanofi access to Vicebio’s molecular clamp technology, which helps the immune system better recognize and respond to viral proteins.

The transaction is expected to be completed in the fourth quarter, pending customary closing conditions. Sanofi stated that the acquisition will not significantly impact its full-year financial guidance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.